However, ESCC, head and neck, and colorectal cancer have relatively high p53 mutation rates and high antibody expression rates, while prostate cancer, glioma, and skin cancer have relatively high mutation rates and low antibody expression rates.12 This evidence concerns the gene TP53 and prostate cancer.